BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Lead Drug Candidate Indicates Strong Orthopoxvirus Activity

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that, in a lethal animal model, its lead drug candidate, NV-387, showed ultra-broad antiviral activity, including activity against the orthopoxvirus family, including smallpox and mpox. According to the announcement, in the model of lung infection by Ectromelia virus, oral dosing with NV-387 showed an increase in lifespan of mice comparable to oral treatment with tecovirimat (TPOXX[R], SIGA), which is currently the approved drug against smallpox.

“We have completed a lethality animal study wherein animals were infected with ectromelia virus into the lungs directly,” stated the company in the press release. “In this study, we found that NV-387 alone treated animals survived 15 days, tecovirimat alone treated animals survived 16 days, and NV-387 plus tecovirimat treated animals survived 19 days, whereas vehicle-treated animals died in 8 days. Therefore, we believe that NV-387 is a viable clinical candidate to be developed by itself for the treatment of poxvirus infections under the US FDA ‘Animal Rule.’ In addition, we believe that the combination of NV-387 and tecovirimat could reduce the potential for escape resistant generation against tecovirimat, as is known with other drug combination studies against viruses.”

To view the full press release, visit https://ibn.fm/a10Cj

About NanoViricides Inc.

NanoViricides is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s lead drug candidate is NV-387 for the treatment of RSV, COVID-19, Long COVID and other respiratory viral infections. Its other advanced candidate is NV-HHV-1 for the treatment of shingles rash, HSV-1 “cold sores” and HSV-2 “genital ulcers.” The company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. To learn more about the company, visit www.NanoViricides.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN